Form 4 for OPRX OptimizeRx Corp
Accepted 2025-10-07 00:00:00 ET · period of report 2025-08-21 · accession 0001628280-25-044426 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-07 | 2025-08-21 | OPRX | D'Silva Andrew J. | Chief Business Off | A - Grant | $0.00 | +10.4K | 47.5K | +28% | $0 |
| D | 2025-10-07 | 2025-08-21 | OPRX | D'Silva Andrew J. | Chief Business Off | A - Grant | $0.00 | +23.4K | 23.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | A | A | 10,417 | $0.00 | 47,514 | D | — | — | (F1) Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 21, 2026, which is the first anniversary of the grant date. |
| 2 | Derivative | Stock Option | 2025-08-21 | A | A | 23,437 | $0.00 | 23,437 | D | $16.14 · — to 2030-08-21 | 23,437 Common Stock | (F2) The stock option vests in three equal annual installments beginning August 21, 2026, the first anniversary of the grant date. |